Wedbush cuts target to USD 23: Denali Therapeutics stock gains 5.13 percent

Published on 10/20/2026 at 21:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Denali reports results on November 5, 2026. Denali Therapeutics stock costs EUR 17.01 on October 20, 2026, up 5.13 percent versus Frankfurt close.

Analyst target and reporting date

Wedbush cut its Denali target from USD 27.00 to USD 23.00 on October 19, 2026.
Denali is scheduled to report third-quarter results on November 5, 2026.
Denali Therapeutics stock costs EUR 17.01 at Lang & Schwarz on October 20, 2026 at 9:01 p.m. CEST, up 5.13 percent versus the Frankfurt close of October 16, 2026.
The Nasdaq quote was USD 19.13 at 3:03 p.m. ET on October 20, 2026, while the market capitalization was USD 3.1 billion.

DNLI, US24823R1059, Illustration mit AI erstellt.

Denali Therapeutics (ISIN US24823R1059) is trading sharply higher in Germany after Wedbush cut its price target from USD 27.00 to USD 23.00 while keeping an Outperform rating on October 19, 2026, as reported by Yahoo Finance. The stock was trading at EUR 17.01 at Lang & Schwarz on October 20, 2026 at 9:01 p.m. CEST, up 5.13 percent versus the Frankfurt close of October 16, 2026 at EUR 16.18.

Wedbush target moves lower

The target reduction leaves Wedbush's USD 23.00 view 20.23 percent above Denali's Nasdaq price of USD 19.13 at 3:03 p.m. ET on October 20, 2026. The rating remained Outperform, so the change lowered the valuation reference without removing the firm's positive stance.

MarketBeat reported on October 10, 2026 that Wall Street Zen had cut Denali from Hold to Sell. The same report cited a broader average target of USD 35.85 and described second-quarter revenue of USD 3.60 million, versus a USD 2.15 million consensus estimate, while diluted earnings per share showed a USD 0.68 loss, MarketBeat reported.

Price sits in its range

Denali's Nasdaq price of USD 19.13 stood between a 52-week low of USD 13.75 and a high of USD 27.30 on October 20, 2026. The level was 29.92 percent below the high and 39.13 percent above the low, placing the stock closer to its yearly low than its yearly high.

The company had a market capitalization of USD 3.1 billion and a negative price-to-earnings ratio of -6.74 on October 20, 2026. Denali's investor page identifies the listing as Nasdaq Global Select Market under ticker DNLI and describes a biotechnology business focused on treatments for neurodegenerative diseases through its TransportVehicle platform.

Valuation and November date

Denali's next scheduled earnings report is November 5, 2026, according to Market Jury's company calendar dated October 19, 2026, which also listed 19 analysts and a USD 33.67 consensus target, Market Jury. That date will put the focus on whether the commercial rollout can improve the revenue base after the USD 3.60 million second-quarter result.

The evening price position

Denali Therapeutics was trading at EUR 17.01 at Lang & Schwarz on October 20, 2026 at 9:01 p.m. CEST, up 5.13 percent versus the Frankfurt close of October 16, 2026 at EUR 16.18. The further course of trading is shown by the continuously updated real-time quote of Denali Therapeutics stock.